ProPhase Labs, Inc. (NASDAQ:PRPH) to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity Forecasts

ProPhase Labs, Inc. (NASDAQ:PRPH) – Equities researchers at Diamond Equity issued their Q1 2025 earnings per share estimates for shares of ProPhase Labs in a research note issued on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings of $0.10 per share for the quarter. The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.12 EPS and Q4 2025 earnings at $0.14 EPS.

ProPhase Labs (NASDAQ:PRPH) last released its earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. The company had revenue of $3.50 million during the quarter, compared to analysts’ expectations of $10.71 million. ProPhase Labs had a negative return on equity of 29.83% and a negative net margin of 37.81%.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of ProPhase Labs in a research note on Wednesday, February 21st.

ProPhase Labs Stock Down 1.9 %

Shares of ProPhase Labs stock opened at $5.06 on Wednesday. The firm has a market cap of $91.33 million, a price-to-earnings ratio of -5.16 and a beta of -0.29. The stock has a 50-day simple moving average of $5.54 and a 200-day simple moving average of $5.00. ProPhase Labs has a 52-week low of $4.05 and a 52-week high of $9.94. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.28 and a quick ratio of 2.10.

Institutional Trading of ProPhase Labs

Large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock valued at $68,000 after acquiring an additional 5,026 shares during the period. HighTower Advisors LLC acquired a new position in ProPhase Labs in the third quarter worth $756,000. Finally, SVB Wealth LLC acquired a new position in ProPhase Labs during the 3rd quarter worth about $208,000. 9.45% of the stock is owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.